July 18, 2019
Pfizer Inc. and its affiliates asked the U.S. Judicial Panel on Multidistrict Litigation Thursday to transfer a suit from West Virginia to Delaware, where 13 nearly identical federal complaints are pending that claim infringement of three drug patents central to a Pfizer breast cancer treatment.